Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania. Show more

1717 Langhorne Newtown Road, Langhorne, PA, 19047, United States

Biotechnology

Healthcare

Market Cap

1.068B

52 Wk Range

$1.89 - $7.00

Previous Close

$5.25

Open

$5.32

Volume

2,319,221

Day Range

$5.10 - $5.38

Enterprise Value

974.7M

Cash

124.4M

Avg Qtr Burn

-22.53M

Insider Ownership

2.27%

Institutional Own.

98.31%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Molgramostim Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.